Lazari Capital Management Inc. Buys 536 Shares of Pfizer Inc. (NYSE:PFE)

Lazari Capital Management Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 2.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,895 shares of the biopharmaceutical company’s stock after buying an additional 536 shares during the period. Lazari Capital Management Inc.’s holdings in Pfizer were worth $529,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of PFE. Capital International Ltd. CA raised its holdings in Pfizer by 2.2% during the fourth quarter. Capital International Ltd. CA now owns 371,336 shares of the biopharmaceutical company’s stock valued at $10,691,000 after buying an additional 7,991 shares in the last quarter. Capital International Sarl grew its position in shares of Pfizer by 9.3% in the fourth quarter. Capital International Sarl now owns 438,138 shares of the biopharmaceutical company’s stock valued at $12,614,000 after purchasing an additional 37,233 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Pfizer by 283.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 705,479 shares of the biopharmaceutical company’s stock valued at $20,311,000 after purchasing an additional 521,677 shares during the last quarter. Crossmark Global Holdings Inc. grew its position in shares of Pfizer by 1.4% in the fourth quarter. Crossmark Global Holdings Inc. now owns 78,863 shares of the biopharmaceutical company’s stock valued at $2,271,000 after purchasing an additional 1,107 shares during the last quarter. Finally, Morningstar Investment Management LLC grew its position in shares of Pfizer by 4.8% in the fourth quarter. Morningstar Investment Management LLC now owns 37,016 shares of the biopharmaceutical company’s stock valued at $1,066,000 after purchasing an additional 1,710 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of several research analyst reports. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Wells Fargo & Company lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, September 16th. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Nine investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Performance

PFE stock opened at $28.67 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a 50 day moving average price of $29.28 and a 200 day moving average price of $28.31. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.11. The stock has a market capitalization of $162.46 billion, a PE ratio of -477.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 EPS. Analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.